JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
NEW YORK, Dec. 12, 2016 -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 19, 2016.
The following 21 securities will be added to the Index:
| Exchange | SYMBOL | COMPANY NAME |
| Nasdaq | AIMT | Aimmune Therapeutics, Inc. |
| Nasdaq | ARLZ | Aralez Pharmaceuticals Inc. |
| Nasdaq | AVXS | AveXis, Inc. |
| Nasdaq | BGNE | BeiGene, Ltd. |
| Nasdaq | BOLD | Audentes Therapeutics |
| Nasdaq | CLCD | CoLucid Pharmaceuticals |
| Nasdaq | CLSD | Clearside Biomedical, Inc. |
| Nasdaq | CYTK | Cytokinetics, Incorporated |
| Nasdaq | EDIT | Editas Medicine, Inc. |
| Nasdaq | GBT | Global Blood Therapeutics |
| Nasdaq | ITCI | Intra-Cellular Therapies |
| Nasdaq | LOXO | Loxo Oncology, Inc. |
| Nasdaq | MNOV | Medicinova Inc |
| Nasdaq | NERV | Minerva Neurosciences |
| Nasdaq | NH | NantHealth, Inc. |
| Nasdaq | NTLA | Intellia Therapeutics, Inc. |
| Nasdaq | NVCR | NovoCure Limited |
| Nasdaq | ONVO | Organovo Holdings Inc |
| Nasdaq | OPK | OPKO Health, Inc. |
| Nasdaq | PRTK | Paratek Pharmaceuticals, Inc. |
| Nasdaq | RGNX | REGENXBIO Inc. |
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 37 securities will be removed from the Index:
| Exchange | SYMBOL | COMPANY NAME |
| Nasdaq | ADHD | Alcobra Ltd. |
| Nasdaq | ADVM | Adverum Biotechnologies, Inc. |
| Nasdaq | AFMD | Affimed N.V. |
| Nasdaq | AGTC | Applied Genetic Technologies Corporation |
| Nasdaq | ANTH | Anthera Pharmaceuticals, Inc. |
| Nasdaq | CARA | Cara Therapeutics, Inc. |
| Nasdaq | CASC | Cascadian Therapeutics, Inc. |
| Nasdaq | CHMA | Chiasma, Inc. |
| Nasdaq | CMRX | Chimerix, Inc. |
| Nasdaq | CNCE | Concert Pharmaceuticals, Inc. |
| Nasdaq | CXRX | Concordia International Corp. |
| Nasdaq | DNAI | ProNAi Therapeutics, Inc. |
| Nasdaq | DRNA | Dicerna Pharmaceuticals, Inc. |
| Nasdaq | DRRX | DURECT Corporation |
| Nasdaq | ECYT | Endocyte, Inc. |
| Nasdaq | EGLT | Egalet Corporation |
| Nasdaq | FLKS | Flex Pharma, Inc. |
| Nasdaq | IMDZ | Immune Design Corp. |
| Nasdaq | IMGN | ImmunoGen, Inc. |
| Nasdaq | INFI | Infinity Pharmaceuticals, Inc. |
| Nasdaq | ITEK | Inotek Pharmaceuticals Corporation |
| Nasdaq | KMPH | KemPharm, Inc. |
| Nasdaq | LIFE | aTyr Pharma, Inc. |
| Nasdaq | MNKD | MannKind Corporation |
| Nasdaq | NDRM | NeuroDerm Ltd. |
| Nasdaq | NEOS | Neos Therapeutics, Inc. |
| Nasdaq | OCUL | Ocular Therapeutix, Inc. |
| Nasdaq | OREX | Orexigen Therapeutics, Inc. |
| Nasdaq | OSIR | Osiris Therapeutics, Inc. |
| Nasdaq | OVAS | OvaScience Inc. |
| Nasdaq | QURE | uniQure N.V. |
| Nasdaq | RGLS | Regulus Therapeutics Inc. |
| Nasdaq | SCLN | SciClone Pharmaceuticals, Inc. |
| Nasdaq | TKAI | Tokai Pharmaceuticals, Inc. |
| Nasdaq | TTPH | Tetraphase Pharmaceuticals, Inc. |
| Nasdaq | VTL | Vital Therapies, Inc. |
| Nasdaq | ZFGN | Zafgen, Inc. |
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
NDAQG
Media Contacts: Peter Gau, Nasdaq +1.212.231.5475 Issuer & Investor Contact: Natasha Selzer, Nasdaq +1.301.978.8623
